Researchers reported evidence that TRPV4 drives aminoglycoside ototoxicity without reducing antimicrobial efficacy. The study highlights a mechanism in which the TRPV4 channel influences both aminoglycoside trafficking and ototoxic effects, aiming to decouple hearing damage from antibacterial activity. The finding is relevant for infectious disease patients who rely on aminoglycosides but face a persistent safety barrier. By identifying a potential therapeutic intervention point upstream of ototoxicity, the work supports future strategies to protect hearing while maintaining drug performance.